← Back to Search

NA

Part 2: Sequence B for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
BMI is ≥ 18.0 to ≤ 32 kg/m2 after rounding to the tenth.
Negative test result for SARS-CoV-2 infection at screening visit and upon initial confinement.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 44 days
Awards & highlights

Study Summary

This trial tests how well a new drug works in healthy adults and how long it stays in their bodies.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 44 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 44 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-903
Area Under the Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUCt) of ABBV-903
Maximum Plasma Concentration (Cmax) of ABBV-903
+3 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: Part 2: Sequence BExperimental Treatment2 Interventions
In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Participants will be followed up for 30 days.
Group II: Part 2: Sequence AExperimental Treatment2 Interventions
In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 2 after a high fat meal. Participants will be followed up for 30 days.
Group III: Part 1: Sequence BExperimental Treatment2 Interventions
In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. Participants will be followed up for 30 days.
Group IV: Part 1: Sequence AExperimental Treatment2 Interventions
In Period 1 on Day 1, participants will receive ABBV-903 Tablet Form 1 after fasting. In Period 2 on Day 1, participants will receive ABBV-903 Tablet Form 2 after fasting. Lastly, in Period 3 on Day 1, participants will receive ABBV-903 Tablet Form 1 after a high fat meal. Participants will be followed up for 30 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ABBV-903 Tablet Form 2
2023
Completed Phase 1
~30
ABBV-903 Tablet Form 1
2023
Completed Phase 1
~30

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

AbbVieLead Sponsor
946 Previous Clinical Trials
496,448 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
387 Previous Clinical Trials
141,129 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the study open to geriatric patients?

"This trial is seeking volunteers aged between 18 and 65."

Answered by AI

What are the risk factors associated with Part 1: Sequence A?

"Due to the limited empirical evidence regarding safety and effectiveness, our team at Power gave Part 1: Sequence A a score of one on its risk scale."

Answered by AI

Who is eligible to enroll in this research project?

"Prospective participants of the trial must be within 18 and 65 years old, with no pre-existing health issues. A cap of 24 patients is in place for this experiment."

Answered by AI

Are participants currently being enrolled in this research endeavor?

"Affirmative. Clinicaltrials.gov data shows that the search for participants is currently in progress; this medical trial was first posted on April 24th 2023 and has since been updated most recently on April 20th 2023. The clinical study requires 24 patients to be recruited from one site."

Answered by AI

What is the aggregate enrollment of this clinical trial?

"Indeed, clinicaltrials.gov reveals that this medical trial is presently accepting patients. The study was first announced on April 24th 2023 and recently edited on the twentieth of April in the same year. A total of 24 participants are being recruited from only one site."

Answered by AI
~13 spots leftby Mar 2025